



BD Vystra™
Disposable Pen

Expertise and
efficiency combined



BD Vystra™ Disposable Pen: Where reliability meets simplicity

Designed and validated to support optimal use and patient confidence.



For biotech and pharmaceutical companies, speed to market and efficiency are key.
As a leader in delivery and injection devices, BD provides the support and industry knowledge you need for an accelerated delivery to market. Partnering with BD allows you to leverage our:

- Strong IP position
- Rigorous development and documentation
- World-class manufacturing capabilities

BD is committed to quality by design and offers biopharmaceutical customers:

- Pre-configured product for select therapies
- Human Factors Evaluation Report capturing the range of Human Factor Studies conducted on the platform products.
- Validated platform IFU available for reference
- Streamlined development process, including documentation package supporting:
 - Cartridge compatibility
 - Needle compatibility
 - Dose accuracy testing per ISO




As patient care increasingly shifts to the home setting³, self-injection devices must be able to accommodate a broad range of patient profiles. Designed for use with a wide range of therapies that require frequent injections or variable dosing, the BD Vystra™ Disposable Pen offers ease of use and adjustable features for disease management.

Benefits for patients

- Easy to use¹
- Optimized design²
- Injection reliability

Patent coverage includes technology embodied by BD's Vystra™ Disposable Pen

- **Robust** proven design based on patient usability and human factor considerations¹
- **Adjustable features** support your drug delivery needs, including variable and multi-dose use, simple dose dialing¹ with audible clicks, and large and clear dose markings
- **Variety of pre-developed** button options and therapeutic dose ranges



As a partner, BD is committed to your success.

BD PartnerPath™ is for customers who value speed to market over customization.

The program offers preselected, prevalidated product configurations for high-demand therapies coupled with a comprehensive documentation package. Building on our deep understanding of your needs, BD Medical-Pharmaceutical Systems has developed this small-scale rapid delivery program to help get your drug through development and to patients more rapidly. Shorten your time to market, streamline your development process!

References:

1. A simulated study of acceptance, preference and willingness to adopt of a new pen injector (BD Vystra™) [internal study], Pont-de-Claix, FR: Becton Dickinson and Company; 2014
2. Design input specification for BD Vystra™ [internal report]. Franklin Lakes, USA: Becton Dickinson and company; 2016
3. Landers, Steven, et al. "The future of home health care: a strategic framework for optimizing value". Home health care management & practice 28.4 (2016): 262-278.

BD Medical

Pharmaceutical Systems

United States

1 Becton Drive
Franklin Lakes, NJ 07417
+1 800 225 3310

Europe

11 rue Aristide-Bergès
38800 Le Pont-de-Claix
France

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05

Becton Dickinson France S.A.S

Share capital: 64 719 915 €

RCS Grenoble B 056 501 711

bd.com

BD, the BD Logo, BD Vystra are trademarks of Becton, Dickinson and Company or its affiliates. © 2020 BD. All rights reserved.

